Mitochondrial DNA Sequencing Test: mtDNA Mutations and Results

Mitochondrial DNA sequencing examines the small circular genome inside mitochondria, the cell structures that generate much of the body’s usable energy. Pathogenic mtDNA variants can cause neurologic, muscular, cardiac, endocrine, hearing, vision, and multisystem disorders. Testing differs from ordinary gene sequencing because each cell contains many mitochondrial genomes. A variant may be present in all copies, called homoplasmy, or in only a proportion, called heteroplasmy. The heteroplasmy level can differ among blood, urine, muscle, liver, and other tissues, and it may change with age. A negative blood result therefore does not always exclude an mtDNA disorder. Whole-mitochondrial-genome sequencing detects point variants and small insertions or deletions, but the assay must also be checked for its ability to detect large mtDNA deletions, depletion, low-level heteroplasmy, and nuclear-gene causes. Result interpretation considers the specific variant, heteroplasmy, tissue, maternal family history, phenotype, functional evidence, and mitochondrial haplogroup. A detected variant may confirm disease, remain uncertain, or be an incidental lineage-associated change with no clinical effect.

• The mitochondrial genome is separate from nuclear DNA and is usually inherited through the maternal line.
• Heteroplasmy means a mixture of normal and variant mtDNA copies within a cell or tissue.
• Heteroplasmy level varies by tissue and does not translate directly into disease severity.
• Blood can miss pathogenic variants that are more detectable in urine, muscle, or another affected tissue.
• Whole mtDNA sequencing may not include large-deletion, depletion, or nuclear mitochondrial-gene analysis.
• Variant classification requires mtDNA-specific criteria, population context, phenotype, and segregation evidence.

Table of Contents

• The mitochondrial genome and inheritance
• When mtDNA sequencing is ordered
• Heteroplasmy, threshold effects, and tissue choice
• Laboratory methods and assay scope
• Interpreting pathogenic and likely pathogenic results
• Variants of uncertain significance and benign variation
• Negative results and additional testing
• Family testing, recurrence, and next steps

The Mitochondrial Genome and Inheritance

Most genetic material is located in the cell nucleus, but mitochondria contain their own genome. Human mitochondrial DNA, or mtDNA, is approximately 16.6 kilobases long and encodes 13 respiratory-chain proteins, 22 transfer RNAs, and two ribosomal RNAs. Hundreds to thousands of mtDNA molecules can be present in one cell, depending on tissue and energy demand.

The mitochondrial respiratory chain depends on both genomes. Only a small fraction of its components are encoded by mtDNA; most mitochondrial proteins are encoded by nuclear genes, made in the cytoplasm, and imported into mitochondria. A person can therefore have a primary mitochondrial disorder caused by an mtDNA variant or by a variant in one of many nuclear genes. Whole mtDNA sequencing addresses only the first category unless ordered as part of a broader panel, exome, or genome test.

Mitochondrial DNA is usually inherited from the egg. A person with a pathogenic mtDNA variant may transmit it to all children, but only children who inherit mitochondria from that person can transmit it to the next generation. A man with an mtDNA disorder generally does not pass the mtDNA variant to his children. This maternal pattern is an important clue but is not always obvious because expression can vary widely among relatives.

The mitochondrial genome does not follow simple dominant or recessive rules. One individual may carry a mixture of variant and nonvariant molecules, and the proportion transmitted to each egg can differ because of the mitochondrial genetic bottleneck. Siblings can therefore inherit substantially different heteroplasmy levels and have different symptoms.

Some mtDNA variants are homoplasmic, meaning nearly all mitochondrial genomes carry the change. Homoplasmy does not automatically mean pathogenicity. Many harmless haplogroup-defining variants are homoplasmic and reflect maternal ancestry. Conversely, some pathogenic variants can be homoplasmic but cause disease only in certain genetic or environmental contexts.

Mitochondrial disease also can arise from a new mtDNA variant or a single large deletion that is not detectable in the mother’s tested tissue. Maternal inheritance is common, but absence of a family history does not exclude an mtDNA disorder [1].

When mtDNA Sequencing Is Ordered

Mitochondrial disease can affect nearly any organ, particularly tissues with high energy requirements. Testing may be considered for unexplained encephalopathy, seizures, developmental regression, stroke-like episodes, ataxia, neuropathy, myopathy, exercise intolerance, cardiomyopathy, conduction disease, hearing loss, optic neuropathy, diabetes, short stature, renal disease, gastrointestinal dysmotility, or a multisystem presentation.

No single symptom is specific. Common disorders, medication effects, nutritional deficiencies, autoimmune disease, infection, and other genetic conditions can resemble mitochondrial disease. The pretest evaluation may include neurologic and physical examination, pedigree, metabolic studies, imaging, hearing and vision assessment, cardiac testing, and review of medications and exposures. Normal lactate does not exclude mitochondrial disease, while elevated lactate is not diagnostic by itself.

Whole mtDNA sequencing may be ordered as:

• a first-line test when the phenotype strongly suggests an mtDNA disorder;
• part of a combined mitochondrial panel that includes nuclear genes;
• reflex testing after a negative nuclear panel or exome;
• testing of another tissue after a negative blood result;
• family testing for a known mtDNA variant;
• prenatal or reproductive testing after a familial variant is established.

A limited targeted test may be appropriate when a well-characterized familial variant is known. For an undiagnosed individual, testing only a few common mtDNA variants can miss rare pathogenic changes. Current laboratory guidelines favor next-generation sequencing of the complete mitochondrial genome, with sensitivity for heteroplasmy and additional analysis for deletions when indicated [2].

The clinical question should specify whether the concern is a point variant, a single large-scale deletion, multiple deletions, or mtDNA depletion. These mechanisms require different assays. A “mitochondrial DNA sequencing” order may not measure the total number of mtDNA copies relative to nuclear DNA, which is needed to diagnose depletion.

Testing is also used in oncology and aging research, but a somatic mtDNA variant found in tumor or population sequencing should not be assumed to cause a primary mitochondrial disorder. This article focuses on constitutional clinical testing.

Heteroplasmy, Threshold Effects, and Tissue Choice

Heteroplasmy is the proportion of mtDNA molecules carrying a variant in the tested sample. A report may state, for example, that a variant was detected at 18% heteroplasmy in blood. This means approximately 18% of analyzed mtDNA molecules carried the change; it does not mean 18% of cells are affected or that disease severity is 18%.

Cells can distribute mtDNA molecules unevenly when they divide, a process called replicative segregation. Over time, one tissue may accumulate more variant mtDNA while another loses it. The threshold at which energy production becomes impaired varies by variant, tissue, and physiologic demand. Symptoms emerge when the functional reserve of a tissue is exceeded, not at one universal percentage.

Blood is convenient but can be a poor specimen for selected variants. Some pathogenic variants decline in blood with age because blood-cell lineages carrying high levels are selected against. The m.3243A>G variant is a classic example: urine epithelial cells may retain a higher and more informative level than blood. Skeletal muscle can be more sensitive for variants associated with myopathy and for large deletions, but biopsy is invasive.

Specimen	Advantages	Limitations
Blood	Easy collection; suitable for many variants and nuclear testing	Some heteroplasmies decline with age or are absent in blood
Urine epithelial cells	Noninvasive; useful for several mtDNA variants	Collection and DNA quality vary; not every laboratory validates urine
Buccal or saliva	Noninvasive alternative tissue	Mixed cell types and variable heteroplasmy; may resemble blood for some variants
Skeletal muscle	High relevance for myopathic disease; useful for deletions and biochemical studies	Invasive; sampling and tissue handling require expertise
Liver, heart, or other tissue	May reflect the affected organ	Usually available only from a clinically indicated procedure

Tissue choice should be planned before declaring a negative test conclusive. Recent cohort studies show meaningful diagnostic yield from urine mitochondrial genome sequencing and reinforce tissue-specific detection [3]. Research also demonstrates that heteroplasmy effects depend on cell type and environment [4].

Heteroplasmy measured by one laboratory at one time should not be compared casually with a result from a different tissue, platform, or detection threshold. Small changes can reflect sampling and analytic variation. Clinical trends are based on phenotype and organ assessment, not repeated heteroplasmy measurements alone.

Laboratory Methods and Assay Scope

Next-generation sequencing is the usual method for whole mtDNA analysis. Because each cell contains many mitochondrial genomes, laboratories can obtain very high read depth. Deep coverage supports detection of heteroplasmy below the level typically visible by Sanger sequencing. The laboratory validates a lower limit of detection, which may differ for single-nucleotide variants, small insertions or deletions, and homopolymer regions.

Short-read NGS can be performed after amplification of the mitochondrial genome or through capture from total DNA. Amplification increases mtDNA representation but can introduce bias and may co-amplify nuclear mitochondrial DNA segments, known as NUMTs. These are mtDNA-like sequences inserted into nuclear chromosomes. Bioinformatic pipelines must distinguish true mitochondrial reads from NUMTs to avoid false calls.

The report should state whether the test detects:

• single-nucleotide variants throughout the mitochondrial genome;
• small insertions and deletions;
• low-level heteroplasmy and its validated cutoff;
• single large-scale deletions;
• multiple mtDNA deletions;
• mtDNA copy number or depletion;
• nuclear genes involved in mitochondrial function.

A sequencing assay may infer a large deletion from read-depth changes, but sensitivity can vary by tissue and deletion level. Long-range PCR, digital PCR, quantitative PCR, Southern blot, or long-read sequencing may provide complementary analysis. Multiple deletions can indicate a nuclear maintenance disorder such as one involving POLG, TWNK, or other genes; identifying the pattern does not identify the nuclear cause.

Whole-exome sequencing sometimes includes mtDNA analysis, but this is not guaranteed. Capture efficiency, depth, heteroplasmy thresholds, and reporting policies differ. The test description must explicitly state that the mitochondrial genome was analyzed and validated. Similarly, standard genome sequencing may have strong mtDNA coverage but should not be assumed to include clinical interpretation of all mitochondrial variant types.

Quality controls assess total reads, coverage uniformity, strand balance, base quality, and contamination. Very low-level variants near the threshold require caution because sequencing errors, NUMTs, and index cross-contamination can mimic heteroplasmy. A 2024 study of sequencing methods emphasizes that detection limits and platform quality materially affect low-level calls [5].

Interpreting Pathogenic and Likely Pathogenic Results

A positive result identifies a pathogenic or likely pathogenic mtDNA variant that fits the laboratory’s classification criteria. The report should include the standardized mitochondrial position, reference and alternate base, affected gene, heteroplasmy in the tested tissue, classification, associated phenotypes, and inheritance information.

Variant interpretation in mtDNA requires specialized criteria. Evidence can include:

• repeated association with a consistent mitochondrial phenotype;
• segregation with disease in maternal relatives;
• higher heteroplasmy in affected than unaffected tissues or relatives;
• functional studies showing impaired respiratory-chain activity;
• conservation and predicted impact for protein-coding or RNA genes;
• rarity beyond what is expected for a benign haplogroup variant;
• single-fiber studies linking the variant to biochemical deficiency;
• de novo occurrence with appropriate maternal testing.

ClinGen’s mtDNA-specific framework modifies general variant-classification rules to account for maternal inheritance, heteroplasmy, threshold effects, haplogroups, and the absence of conventional intronic splicing [6].

A pathogenic classification does not predict the exact clinical course. The same variant can cause different syndromes, and people with similar heteroplasmy can have different organ involvement. Age, tissue distribution, nuclear background, environmental exposures, and stochastic segregation contribute to variability.

The reported blood heteroplasmy should not be used as a simple severity score. A low blood level may coexist with a much higher level in muscle or brain. Conversely, a moderate or high level in one tissue may not produce the same disease in every person. Certain variants have better-established genotype-heteroplasmy relationships than others, but counseling remains probabilistic.

A positive mtDNA result may prompt evaluation of organs commonly affected by that variant: hearing, vision, cardiac rhythm and structure, glucose regulation, renal function, neurologic status, and muscle function. Management should be coordinated by clinicians familiar with mitochondrial disease. Some medications and anesthetic considerations may require condition-specific review.

When a variant is detected in a child, maternal testing can determine whether it is inherited or apparently de novo. A negative maternal blood test may not exclude low-level heteroplasmy in another maternal tissue or in oocytes. Recurrence counseling must account for assay sensitivity and variant mechanism.

Variants of Uncertain Significance and Benign Variation

Every mitochondrial genome contains variants. Many define haplogroups and have no disease effect. A clinical report may omit common benign changes or list them separately. Finding several mtDNA variants is therefore expected and does not mean several diagnoses.

A variant of uncertain significance, or VUS, lacks enough evidence to be classified as pathogenic or benign. Uncertainty is common for rare changes in mitochondrial tRNA or protein-coding genes because family data and functional studies may be limited. A VUS should not be used alone to make irreversible medical or reproductive decisions.

Heteroplasmy can contribute evidence but does not settle classification. A low-level variant may be pathogenic in the right context or may represent age-related somatic change. A high-level variant may be a benign haplogroup marker. The location, known disease mechanism, tissue distribution, and maternal segregation are essential.

Family testing can sometimes help. If a variant is present at high levels in several healthy older maternal relatives, pathogenicity may become less likely, although reduced penetrance and tissue differences must be considered. If it is enriched in affected relatives or tissues, evidence may strengthen. Testing should be designed with a genetics professional rather than offered indiscriminately to relatives.

Functional studies on muscle can support interpretation when histochemistry, respiratory-chain enzyme analysis, or single-fiber testing shows a relationship between mutant load and biochemical deficiency. These invasive studies are not necessary for every VUS and should be pursued only when likely to change diagnosis or management.

Laboratories may reclassify variants as new evidence emerges. Patients should retain the report and ask how reanalysis is handled. A VUS is not a “partial positive” and should not be presented as the confirmed cause of symptoms.

Negative Results and Additional Testing

A negative whole mtDNA sequence result means no reportable pathogenic or likely pathogenic sequence variant was found within the assay’s validated range. It does not exclude mitochondrial disease.

The first question is whether the right tissue was tested. If blood was negative and the phenotype remains strongly suggestive, urine, muscle, or another affected tissue may reveal a variant absent or very low in blood. The choice should be variant- and phenotype-informed; an invasive muscle biopsy is not automatically the next step for every patient.

The second question is whether the assay included the relevant variant types. Large deletions, multiple deletions, and depletion may require separate analysis. Depletion is a reduced amount of mtDNA relative to nuclear DNA and cannot be diagnosed by sequence analysis alone. A large deletion may be detectable only in muscle at a clinically meaningful level.

The third question is whether a nuclear gene is responsible. Most proteins required for mitochondrial function are nuclear encoded. A broad nuclear mitochondrial-disease panel, exome sequencing, or genome sequencing may be appropriate. Trio testing can help identify de novo and recessive variants. Copy-number analysis and repeat-expansion testing may also be needed depending on the phenotype.

A negative result can also reflect an unknown disease gene, deep intronic or regulatory variant, low-level mosaicism below detection, complex structural variant, or a non-genetic condition. RNA studies, long-read sequencing, metabolomics, or research enrollment may be considered in unresolved cases.

Biochemical and pathology studies remain useful when genetic testing is inconclusive. Muscle histology, respiratory-chain enzyme analysis, or other specialized tests can demonstrate mitochondrial dysfunction, though findings may be nonspecific. The diagnostic plan should balance invasiveness, expected yield, and whether the result will change care.

Family Testing, Recurrence, and Next Steps

After a pathogenic mtDNA result, maternal relatives may be offered targeted testing with counseling. Testing only blood can underestimate heteroplasmy for some variants, so specimen choice should follow the laboratory and variant-specific recommendations. Relatives can carry the variant without current symptoms and may benefit from baseline organ assessment when evidence supports surveillance.

Recurrence risk is complex. A person with a heteroplasmic mtDNA variant can transmit a wide range of levels to different children. The level measured in blood does not predict the level in eggs precisely. For some variants, specialized reproductive options include prenatal diagnosis, preimplantation genetic testing for mitochondrial disease, donor oocytes, and—in jurisdictions where available—mitochondrial donation. Accuracy and residual risk depend on the variant and technique.

Single large-scale deletions are often sporadic and may carry a lower maternal recurrence risk than inherited point variants, but low-level maternal mosaicism is possible. Nuclear-gene mitochondrial disorders follow autosomal recessive, autosomal dominant, or X-linked inheritance according to the gene. This is another reason to establish whether the cause is mtDNA or nuclear DNA.

Practical questions after testing include:

1. Was the complete mitochondrial genome sequenced, and at what heteroplasmy threshold?
2. Did the assay evaluate large deletions and depletion?
3. Is the tested tissue appropriate for the suspected variant?
4. Does the phenotype fit the reported variant at the observed tissue level?
5. Should nuclear mitochondrial genes be tested?
6. Which maternal relatives should receive targeted testing or clinical evaluation?
7. What organ surveillance and medication precautions are recommended?

A mitochondrial specialist, neurologist, medical geneticist, and genetic counselor can coordinate interpretation. The result should be integrated with clinical findings rather than used as a stand-alone label. Keep the original report because future reclassification, tissue testing, and reproductive counseling depend on the exact variant notation, heteroplasmy, specimen, and method.

References

• Primary Mitochondrial Disorders Overview. 2021. GeneReviews clinical reference.
• Genetic testing for mitochondrial disease: the United Kingdom best practice guidelines. 2023. Professional guideline.
• Genetic landscape of primary mitochondrial diseases in patients with pathogenic mitochondrial DNA variants. 2024. Clinical cohort study.
• Origins of tissue and cell-type specificity in mitochondrial DNA disease. 2024. Review article.
• The quality and detection limits of mitochondrial heteroplasmy sequencing. 2024. Methods study.
• Specifications of the ACMG/AMP Standards and Guidelines for Mitochondrial DNA Variant Interpretation. 2020. Variant-interpretation standard.

Disclaimer

This article provides general education and cannot diagnose mitochondrial disease or interpret an individual mtDNA result. Heteroplasmy, tissue choice, and assay scope require specialist review, and management or reproductive decisions should use the complete report with a mitochondrial clinician and genetic counselor. A negative blood test should not be considered definitive when clinical suspicion remains high.